Full-Time
Vice President New Ventures
Asset Selection
Posted on 9/8/2026
RTW Investments
Lifecycle-focused life sciences investor
Compensation Overview
$425k/yr
New York, NY, USA
In Person
New York-based role with approximately 15% travel.
Bachelor's, Master's, PhD
 Finance & Banking (1) |
|---|
Get referred to RTW Investments
See people who can refer or advise you
- A bachelor's degree in biological sciences is required.
- At least 5 years of experience focused on the biotechnology or pharmaceutical sector is required, although MD/PhD candidates seeking a career switch may be considered with fewer than 5 years of experience.
- Ability to operate independently on strategic and tactical tasks and clearly articulate the process involved.
- Investor mindset and deep experience producing research notes.
- Strong understanding of biological sciences.
- Strong written and verbal communication skills.
- Demonstrated tenacity in conducting detailed research and presenting findings.
- New York-based availability and willingness to travel approximately 15%.
- Source and maintain a pipeline of novel drug development ideas for NewCos within assigned therapeutic areas.
- Conduct proprietary research analyzing assets across science, disease, commercial, intellectual property, chemistry, manufacturing and controls, clinical development, regulatory, and valuation areas.
- Write, pitch, and maintain investment notes for company ideas.
- Build pitch decks including recommended deal terms, clinical development, and financing.
- Develop expertise within assigned therapeutic areas.
- Attend relevant medical, banking, and partnering conferences.
- Convert ideas into NewCos with successful profit and loss performance.
- An advanced degree, specifically an MD or PhD, is strongly preferred.
- At least 5 years of biotechnology or pharmaceutical sector experience in a buy-side role is preferred.
- Relevant academic or industry experience in the life sciences is preferred.
RTW Investments, LP focuses on life sciences across the full investment lifecycle, moving assets from early research through commercialization. Its activities include creating companies from academic work, venture and crossover investing, and public-market positions, with discretionary advisory services for its Flagship and Innovation funds. The firm differentiates itself by combining early-stage company creation with later-stage and public-market investments, enabling long-term partnerships and deeper involvement, with offices in New York, London, and Shanghai. Its goal is to bring transformative biopharmaceutical and medical-technology assets to market, improving patient outcomes while delivering returns for its funds.
Company Size
N/A
Company Stage
N/A
Total Funding
$13.4B
Headquarters
New York City, New York
Founded
2010
Get referred to RTW Investments
See people who can refer or advise you
Simplify's Take
What believers are saying
- BioMarin bought Alesta in August 2026, validating RTW’s portfolio-construction playbook.
- RTW backed Candel’s $100 million royalty financing in February 2026.
- RTW announced seven and eight M&A outcomes since summer 2025, per April 2026.
What critics are saying
- RTW Bio held 70.9% public equities and 24.0% private investments on 2025-12-31.
- Top ten 13F positions represented 47.7% of reported value as of 2026-08.
- Clinical failures at Madrigal, Insmed, Protagonist, or PTC erase marks within quarters.
What makes RTW Investments unique
- RTW spans company creation to public markets, unlike single-stage biotech investors.
- Roderick Wong’s team combines MD, MBA, and 2026 cross-border scientific underwriting.
- RTW keeps monetizing through 2026 M&A, royalty deals, and IPOs.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Life Insurance
401(k) Retirement Plan
Company News
Avere Therapeutics announced a $500 million private placement to advance AVR-001, its once-weekly oral IL-23 receptor antagonist for inflammatory diseases. Leading healthcare investors including Venrock Healthcare Capital Partners, General Atlantic, Blackstone Multi-Asset Investing, and Wellington Management participated in the funding round. Combined with a previously announced $320 million concurrent private investment, the proceeds will fully fund Avere's operations through 2029. The financing will close alongside Avere's merger with NextCure, expected in the second half of 2026. Upon completion, the combined company will operate as Avere Therapeutics and trade on Nasdaq under ticker symbol "AVRX." Avere is initially developing AVR-001 for psoriasis, with potential expansion into ulcerative colitis, Crohn's disease, and psoriatic arthritis.
Tarsus Pharmaceuticals has secured $125 million through an oversubscribed private placement equity financing. The transaction includes participation from investors in Alkeus Pharmaceuticals, which Tarsus announced it would acquire earlier the same day. Notable investors include TCGX, Bain Capital Life Sciences, Wellington Management, ADAR1 Capital Management, Sirenia Capital Management LP, RTW Investments, and Vestal Point Capital. The company is selling 2,098,519 shares of common stock at $56 per share and pre-funded warrants to purchase 133,625 additional shares. The financing is expected to close on 7 August 2026. Tarsus intends to use the proceeds to fund clinical development, commercial activities, and general corporate purposes. Barclays is serving as lead placement agent, with BofA Securities and William Blair as co-placement agents.
Mentari Therapeutics, a biotechnology company developing migraine prevention therapies, has secured $200 million in a private placement from leading healthcare investors. The funding will support the development of Mentari's pipeline of targeted biologics for migraine treatment. Investors include Fairmount, ADAR1 Capital Management, Venrock Healthcare Capital Partners, Sirenia Capital Management, Janus Henderson Investors, Blackstone Multi-Asset Investing, RTW Investments, Deep Track Capital, Vivo Capital, Commodore Capital, BB Biotech, and others. The financing extends Mentari's cash runway into 2029 and through Phase 2a readouts on two PACAP-targeted lead programmes, including MT-002. The private placement will close immediately before Mentari's merger with InMed Pharmaceuticals and concurrently with a previously announced $290 million private placement. Jefferies, TD Cowen, Stifel, and Guggenheim Securities are acting as placement agents.
/PRNewswire/ -- Mentari Therapeutics, Inc. ("Mentari"), a privately-held biotechnology company developing therapies for migraine prevention, today announced a...
Expected to extend cash runway into the second quarter of 2027, supporting additional follow-up for 2L+ R/M HNSCC patients treated with MICVO at or below a...